查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083987

白血病治療市場：按類型、作用機制、治療階段、給藥途徑、年齡層和最終用戶分類－2026-2032年全球市場預測

Leukemia Therapeutics Market by Type, Mechanism of Action, Line of Therapy, Route of Administration, Age Group, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，白血病治療市場將成長至 296.3 億美元，複合年成長率為 7.18%。

主要市場統計數據
基準年 2025 182.3億美元
預計年份：2026年 194.8億美元
預測年份 2032 296.3億美元
複合年成長率 (%) 7.18%

白血病治療市場概覽

精準醫療、基於微小殘留病灶（MRD）的療法以及標靶治療在急性急性骨髓性白血病（AML）、急性淋巴細胞白血病（ALL）、慢性淋巴性白血病白血病（CLL）和慢性骨髓性白血病治療市場。檢驗的分子標靶、基因組檢測的普及以及結合蛋白酪氨酸激酶抑制劑、BCL-2抑制劑、單株抗體、雙特異性抗體、抗體藥物複合體（ADC）和CAR-T細胞療法的治療標準的建立，是推動市場成長的主要動力。最大的商業性機會在於保險公司、癌症中心和製藥公司將實證醫學證據與持續緩解、降低毒性、門診可行性和真實世界臨床價值相結合的領域。

白血病治療的變革性變化

白血病的治療方法正從廣譜細胞毒性化療轉向以實證醫學為基礎、以病人為中心的最佳化治療方案。在慢性骨髓性白血病（CML）中，BCR-ABL蛋白酪氨酸激酶抑制劑顯著提高了存活率，並成為慢性癌症控制的標竿。在慢性淋巴性白血病（CLL）中，基於BTK抑制劑和BCL-2的固定週期方案減少了對化療免疫療法的依賴。在急性骨髓性白血病（AML）和急性淋巴性白血病（ALL）中，基因組分層、微小殘留疾病（MRD）檢測和免疫療法正在改變誘導治療、強化治療、維持治療和復發預防的策略。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過加速標靶發現、最佳化臨床試驗設計、改進影像和流式細胞技術分析以及支援基於多組體學數據和電子健康記錄數據的累積預測，對白血病治療整體產生了累積性影響。人工智慧模型擴大被用於整體分子亞組、預測復發以及將患者與臨床試驗進行匹配，但其臨床應用取決於前瞻性檢驗、可解釋性和符合監管標準的性能。

關於白血病治療藥物的關鍵區域見解

北美地區憑藉其高密度的臨床試驗、快速的FDA腫瘤藥物核准流程、先進的生物標記應用以及廣泛的學術癌症網路，仍然是白血病治療領域的領先地區。美國在慢性淋巴細胞白血病（CLL）、急性髓性白血病（AML）、急性淋巴細胞白血病（ALL）和慢性粒細胞白血病（CML）新療法的推廣方面處於領先地位，而加拿大則受益於集中化的醫療技術評估、省級腫瘤項目以及基於指南的癌症治療。

按經濟區分類的關鍵群體洞察

在東南亞國協，隨著全民健康覆蓋範圍的擴大、區域癌症控制計畫的實施以及私營部門對腫瘤學的投資，白血病治療正在不斷改善。然而，各國在分子診斷、血液病理學、移植服務和先進免疫療法的可近性方面存在顯著差異。海灣合作理事會（GCC）國家的醫療衛生系統優先發展專科癌症治療、提升國內臨床能力、建設轉診中心和發展醫療旅遊，在明確的報銷途徑和治療方案的指導下，能夠滿足對高品質白血病治療的需求。

主要國家白血病治療趨勢

美國在FDA癌症計畫和國家癌症研究所（NCI）網路的支持下，在白血病治療藥物的研發、CAR-T療法的引入以及研究者主導的臨床試驗方面發揮著主導作用。加拿大則強調成本效益、臨床療效以及各省之間的公平可近性。墨西哥和巴西是拉丁美洲的關鍵市場，公共醫療保險報銷、私人癌症治療、診斷的可及性以及生物相似藥的普及程度都會影響白血病治療藥物的可及性。

為行業領導者提供的實用建議

產業領導者應優先考慮以生物標記定義的適應症、考慮微小殘留病灶（MRD）的綜合開發計劃，以及能夠實現門診治療和長期治療依從性的差異化安全性特徵。臨床計畫應涵蓋多樣化的患者群體，包括老年患者和身體狀況合格的患者，並進行反映當前治療標準（而不僅僅是傳統化療）的真實世界對比。

調查方法

本執行摘要基於二手研究，資訊來源了權威的公共資源，包括全球癌症發病率資料庫、監管公告、同行評審的血液學文獻、臨床實踐指南和衛生技術評估（HTA）框架。主要參考文獻包括世界衛生組織（WHO）、國際癌症研究機構（IARC）、美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）、美國國家癌症研究所（NCI）以及各大血液學會等機構。

結論

白血病治療正進入一個以分子精準性、持續緩解、可控毒性和可靠的真實世界臨床價值為基礎的臨床分化新階段。標靶治療、免疫療法和細胞療法正在改善整體白血病亞型的治療效果，但不同地區和收入水平的患者獲得治療的機會仍有差異。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 白血病治療市場：依類型分類

  • 急性淋巴性白血病（ALL）
  • 急性骨髓性白血病（AML）
  • 慢性淋巴性白血病（CLL）
  • 慢性骨髓性白血病（CML）
  • 毛細胞白血病（HCL）
  • 幼年型骨髓單核細胞白血病（JMML）
  • T細胞前淋巴球白血病（T-PLL）

第8章：白血病治療市場：依作用機制分類

  • 免疫療法
    • 雙特異性T細胞銜接器（BiTEs）
    • CAR-T細胞療法
    • 免疫查核點抑制劑
    • 單株抗體
  • 標靶治療
    • BCL-2抑制劑
    • CDK抑制劑
    • FLT3抑制劑
    • IDH1/IDH2抑制劑
    • PI3K抑制劑
    • 蛋白酪氨酸激酶抑制劑（TKIs）

第9章：白血病治療市場：依治療階段分類

  • 一線治療
  • 二線治療/補救性治療

第10章：白血病治療市場：依給藥途徑分類

  • 鞘內給藥
  • 靜脈注射（IV）
  • 口服
  • 皮下（SC）

第11章：白血病治療市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第12章 白血病治療市場：依最終使用者分類

  • 學術研究機構
  • 癌症治療中心
  • 醫院
  • 專科診所

第13章：白血病治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 白血病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 白血病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Celgene Corporation by Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EUSA Pharma（UK）Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Servier Pharmaceuticals LLC
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4342CA3265BE

The Leukemia Therapeutics Market is projected to grow by USD 29.63 billion at a CAGR of 7.18% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.23 billion
Estimated Year [2026] USD 19.48 billion
Forecast Year [2032] USD 29.63 billion
CAGR (%) 7.18%

Leukemia Therapeutics Market Introduction

Leukemia therapeutics are being reshaped by precision medicine, measurable residual disease (MRD)-guided care, and expanding use of targeted agents across acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Market momentum is supported by validated molecular targets, broader genomic testing, and treatment standards that increasingly combine tyrosine kinase inhibitors, BCL-2 inhibition, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T cell therapies. The commercial opportunity is strongest where payers, cancer centers, and manufacturers align evidence generation with durable remission, toxicity reduction, outpatient feasibility, and real-world value.

Transformative Shifts in Leukemia Care

The leukemia treatment landscape has shifted from broadly cytotoxic chemotherapy toward biologically defined, patient-specific regimens. In CML, BCR-ABL tyrosine kinase inhibitors transformed survival and created a benchmark for chronic cancer control. In CLL, BTK inhibitors and BCL-2-based fixed-duration regimens have reduced reliance on chemoimmunotherapy. In AML and ALL, genomic stratification, MRD testing, and immunotherapies are changing induction, consolidation, maintenance, and relapse strategies.

Transformative shifts also include earlier-line use of targeted combinations, expanding transplant alternatives, and growing clinical interest in time-limited therapy. Regulators and clinicians are emphasizing endpoints such as event-free survival, MRD negativity, complete remission with incomplete hematologic recovery, overall survival, and patient-reported outcomes. These changes favor organizations with differentiated mechanisms, companion diagnostics, scalable manufacturing, and evidence packages that address both efficacy and health-system affordability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative impact across leukemia therapeutics by accelerating target discovery, optimizing trial design, improving image and flow-cytometry interpretation, and supporting risk prediction from multi-omic and electronic health record data. AI-enabled models are increasingly used to identify molecular subgroups, predict relapse, and match patients to trials, although clinical adoption depends on prospective validation, explainability, and regulatory-grade performance.

The most immediate commercial value is in operational efficiency: faster site selection, better patient screening, adaptive trial analytics, pharmacovigilance signal detection, and real-world evidence generation. AI can also improve manufacturing quality control for cell therapies and support dose optimization for combination regimens. Leaders must address bias, data privacy, interoperability, and medical oversight because AI tools in oncology influence high-risk treatment decisions and must comply with evolving FDA, EMA, and data-protection expectations.

Key Regional Insights for Leukemia Therapeutics

North America remains a leading region for leukemia therapeutics because of high clinical-trial density, rapid FDA oncology review pathways, strong biomarker adoption, and broad access to academic cancer networks. The United States drives uptake of novel CLL, AML, ALL, and CML therapies, while Canada benefits from centralized health technology assessment, provincial oncology programs, and guideline-based cancer care.

Europe combines advanced hematology infrastructure with pricing and reimbursement scrutiny, making comparative value evidence essential across major national health systems. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia scale genomic testing, domestic clinical development, and oncology reimbursement for targeted leukemia therapies. Latin America shows rising demand, especially in Brazil and Mexico, but access gaps remain due to uneven diagnostic capacity and public-sector budget limitations. The Middle East is investing in tertiary oncology centers and specialty care, particularly in Gulf states, where referral networks and high-acuity hospitals support advanced therapies. Africa faces the highest constraints in diagnostics, specialist capacity, transplant availability, and drug affordability, making partnerships, training, and essential-medicine access critical for improving leukemia outcomes.

Key Group Insights Across Economic Blocs

ASEAN markets are improving leukemia care through expanding universal health coverage, regional cancer plans, and private-sector oncology investment, although access to molecular diagnostics, hematopathology, transplant services, and advanced immunotherapies varies significantly by country. GCC health systems are prioritizing specialty oncology, domestic clinical capacity, referral-center development, and medical tourism, supporting demand for premium leukemia therapies when reimbursement pathways and treatment protocols are clearly defined.

The European Union is influential through centralized EMA review, joint clinical assessment under evolving health technology frameworks, rare-disease policy alignment, and strong cross-border hematology research networks. BRICS countries represent a large patient base and growing local manufacturing capacity, with China and India especially important for trial recruitment, biosimilar competition, and cost-sensitive access strategies. G7 markets remain the highest-value innovation cluster due to mature reimbursement systems, public research funding, comprehensive cancer centers, and specialty care infrastructure. NATO overlap is commercially relevant because many member countries share advanced procurement standards, supply-chain resilience priorities, and health-system security planning that influence continuity of oncology medicine supply.

Key Country Insights in Leukemia Therapeutics

The United States leads in leukemia drug launches, CAR-T adoption, and investigator-sponsored research, supported by FDA oncology programs and National Cancer Institute networks. Canada emphasizes cost-effectiveness, clinical benefit, and equitable provincial access. Mexico and Brazil are important Latin American markets where public reimbursement, private oncology care, diagnostic availability, and biosimilar penetration shape uptake of leukemia therapeutics.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong hematology expertise with formal health technology assessment, centralized or regional reimbursement review, and guideline-driven care, while Russia maintains demand but faces supply-chain and geopolitical constraints. China has become a major engine for leukemia trials, domestic BTK inhibitor development, CAR-T research, and broader oncology reimbursement reform. India offers large patient volume and expanding specialty hospitals but remains highly price-sensitive, with access influenced by out-of-pocket spending and public insurance expansion. Japan and South Korea provide advanced diagnostics, aging-population demand, strong academic hematology networks, and innovation-friendly regulatory pathways. Australia supports early adoption through clinical trials, public reimbursement review, and strong hematology cooperative groups.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-defined indications, MRD-integrated development plans, and differentiated safety profiles that enable outpatient use and longer treatment adherence. Clinical programs should include diverse populations, elderly and unfit patients, and real-world comparators that reflect current standards of care rather than legacy chemotherapy alone.

Manufacturers should build access strategies early by aligning price, evidence, and outcomes with payer expectations. Companion diagnostics, decentralized trial capabilities, and partnerships with cancer centers can improve patient identification and enrollment. Developers of cell and gene therapies should invest in manufacturing reliability, vein-to-vein time reduction, toxicity management education, and regional treatment networks. Across all modalities, AI governance, pharmacovigilance readiness, and supply-chain resilience are now strategic requirements rather than support functions.

Research Methodology

This executive summary is grounded in secondary research from authoritative public sources, including global cancer incidence databases, regulatory agency communications, peer-reviewed hematology literature, clinical-practice guidelines, and health technology assessment frameworks. Core references include organizations such as the World Health Organization, International Agency for Research on Cancer, U.S. FDA, European Medicines Agency, National Cancer Institute, and major hematology societies.

Insights are synthesized through market segmentation by leukemia subtype, therapy class, mechanism of action, line of therapy, region, and access environment. The analysis emphasizes verified clinical and commercial trends, including approved therapies, guideline-supported treatment evolution, trial activity, diagnostic adoption, reimbursement dynamics, and regional infrastructure. No unsupported market-size, market-share, or forecasting claims are used; conclusions reflect evidence-backed patterns and observable industry developments.

Conclusion

Leukemia therapeutics are entering a new phase in which clinical differentiation depends on molecular precision, durable remission, manageable toxicity, and credible real-world value. Targeted agents, immunotherapies, and cellular therapies are improving outcomes across major leukemia subtypes, but access remains uneven across regions and income levels.

The next competitive advantage will come from integrating diagnostics, data science, manufacturing excellence, and payer-ready evidence into one coordinated strategy. Organizations that can demonstrate survival benefit, MRD-driven depth of response, quality-of-life improvement, and scalable delivery will be best positioned in the global leukemia therapeutics market. As AI and precision oncology mature, industry leaders must balance speed of innovation with rigorous validation, affordability, and equitable patient access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Leukemia Therapeutics Market, by Type

  • 7.1. Acute Lymphoblastic Leukemia (ALL)
  • 7.2. Acute Myeloid Leukemia (AML)
  • 7.3. Chronic Lymphocytic Leukemia (CLL)
  • 7.4. Chronic Myeloid Leukemia (CML)
  • 7.5. Hairy Cell Leukemia (HCL)
  • 7.6. Juvenile Myelomonocytic Leukemia (JMML)
  • 7.7. T-cell Prolymphocytic Leukemia (T-PLL)

8. Leukemia Therapeutics Market, by Mechanism of Action

  • 8.1. Immunotherapy
    • 8.1.1. Bispecific T-cell Engagers (BiTEs)
    • 8.1.2. CAR-T Cell Therapy
    • 8.1.3. Immune Checkpoint Inhibitors
    • 8.1.4. Monoclonal Antibodies
  • 8.2. Targeted Therapy
    • 8.2.1. BCL-2 Inhibitors
    • 8.2.2. CDK Inhibitors
    • 8.2.3. FLT3 Inhibitors
    • 8.2.4. IDH1/IDH2 Inhibitors
    • 8.2.5. PI3K Inhibitors
    • 8.2.6. Tyrosine Kinase Inhibitors (TKIs)

9. Leukemia Therapeutics Market, by Line of Therapy

  • 9.1. First-Line Therapy
  • 9.2. Second-Line / Salvage Therapy

10. Leukemia Therapeutics Market, by Route of Administration

  • 10.1. Intrathecal
  • 10.2. Intravenous (IV)
  • 10.3. Oral
  • 10.4. Subcutaneous (SC)

11. Leukemia Therapeutics Market, by Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Leukemia Therapeutics Market, by End-User

  • 12.1. Academic Research Institutes
  • 12.2. Cancer Treatment Centers
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Leukemia Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Leukemia Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Leukemia Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. Biogen Inc.
  • 17.5. Celgene Corporation by Bristol Myers Squibb Company
  • 17.6. Eisai Co., Ltd.
  • 17.7. Eli Lilly and Company
  • 17.8. EUSA Pharma (UK) Limited
  • 17.9. F. Hoffmann-La Roche Ltd.
  • 17.10. Gilead Sciences, Inc.
  • 17.11. GlaxoSmithKline PLC
  • 17.12. Incyte Corporation
  • 17.13. Johnson & Johnson Services, Inc.
  • 17.14. Novartis AG
  • 17.15. Pfizer Inc.
  • 17.16. Servier Pharmaceuticals LLC
  • 17.17. Takeda Pharmaceutical Company Limited
  • 17.18. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LEUKEMIA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LEUKEMIA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LEUKEMIA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LEUKEMIA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC MYELOID LEUKEMIA (CML) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC MYELOID LEUKEMIA (CML) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC MYELOID LEUKEMIA (CML) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HAIRY CELL LEUKEMIA (HCL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HAIRY CELL LEUKEMIA (HCL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HAIRY CELL LEUKEMIA (HCL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BISPECIFIC T-CELL ENGAGERS (BITES) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BISPECIFIC T-CELL ENGAGERS (BITES) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BISPECIFIC T-CELL ENGAGERS (BITES) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BCL-2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CDK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CDK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CDK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IDH1/IDH2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IDH1/IDH2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IDH1/IDH2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PI3K INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PI3K INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PI3K INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SECOND-LINE / SALVAGE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SECOND-LINE / SALVAGE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SECOND-LINE / SALVAGE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUBCUTANEOUS (SC) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUBCUTANEOUS (SC) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SUBCUTANEOUS (SC) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER TREATMENT CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 169. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 172. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GCC LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. G7 LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 208. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. NATO LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 341. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)